Document/ExhibitDescriptionPagesSize 1: 8-K Current Report HTML 51K
5: R1 Document and Entity Information HTML 45K
8: XML IDEA XML File -- Filing Summary XML 11K
6: XML XBRL Instance -- hae-20220805_htm XML 21K
7: EXCEL IDEA Workbook of Financial Reports XLSX 8K
3: EX-101.LAB XBRL Labels -- hae-20220805_lab XML 66K
4: EX-101.PRE XBRL Presentations -- hae-20220805_pre XML 33K
2: EX-101.SCH XBRL Schema -- hae-20220805 XSD 10K
9: JSON XBRL Instance as JSON Data -- MetaLinks 11± 17K
10: ZIP XBRL Zipped Folder -- 0000313143-22-000045-xbrl Zip 16K
(Address of principal executive offices, including zip code)
telephone number, including area code: i781-i848-7100
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing
is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Name of each exchange on which registered
stock, $.01 par value per share
iNew York Stock Exchange
Indicate by check mark whether the
registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging Growth Company
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
August 5, 2022, the Board of Directors of Haemonetics Corporation (the “Company”) appointed James C. D’Arecca, Executive Vice President, Chief Financial Officer, as the Company’s principal accounting officer in connection with the previously reported departure of Dan Goldstein, Vice President, Corporate Controller, on or about August 9, 2022. Mr. D’Arecca also serves as the Company’s principal financial officer and biographical information with respect to Mr. D’Arecca is incorporated herein from Item 5.02 of the Form 8-K filed by the Company with the SEC on March 21,
Item 5.07 Submission of Matters to a Vote of Security Holders.
The Company’s 2022 Annual Meeting of Shareholders was held on Friday, August 5, 2022. Of the 51,299,384 shares outstanding and entitled to vote at the meeting, 48,277,405 shares were represented at the meeting, constituting a quorum of 94.1%.
The results of the votes for each proposal considered at the meeting are set forth below:
1. The shareholders elected each of Christopher A. Simon, Robert E. Abernathy, Catherine M. Burzik, Michael
J. Coyle, Charles J. Dockendorff, Lloyd E. Johnson, Mark W. Kroll, Claire Pomeroy and Ellen M. Zane as directors for one-year terms expiring in 2023 based upon the following votes:
The shareholders approved, on an advisory basis, the compensation of the Company’s named executive officers based upon the following votes:
3. The shareholders ratified the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending April 1, 2023 based upon the following votes:
to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.